These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15199455)

  • 21. Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
    Zhou SF; Zhou ZW; Huang M
    Toxicology; 2010 Dec; 278(2):165-88. PubMed ID: 19715737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.
    Samardzija M; Topić E; Stefanović M; Zibar L; Samardzija G; Balen S; Vcev A; Domanović D; Mirat J; Barbić J
    Coll Antropol; 2008 Jun; 32(2):557-64. PubMed ID: 18756910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical consequences of cytochrome P450 2C9 polymorphisms.
    Kirchheiner J; Brockmöller J
    Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Racial and ethnic differences in warfarin response.
    El Rouby S; Mestres CA; LaDuca FM; Zucker ML
    J Heart Valve Dis; 2004 Jan; 13(1):15-21. PubMed ID: 14765833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.
    Andersson ML; Eliasson E; Lindh JD
    Pharmacogenomics; 2012 May; 13(7):757-62. PubMed ID: 22594507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations.
    Wiwanitkit V
    Clin Appl Thromb Hemost; 2006 Apr; 12(2):219-22. PubMed ID: 16708125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warfarin dose requirement and CYP2C9 polymorphisms.
    Halkin H; Lubetsky A
    Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
    [No Abstract]   [Full Text] [Related]  

  • 28. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
    Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
    Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
    [No Abstract]   [Full Text] [Related]  

  • 29. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
    King BP; Khan TI; Aithal GP; Kamali F; Daly AK
    Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.
    Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
    Drug Metab Dispos; 2004 May; 32(5):484-9. PubMed ID: 15100169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Ned Tijdschr Geneeskd; 2001 Feb; 145(7):312-5. PubMed ID: 11234294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevalence of CYP2C9 polymorphisms in the south of Europe.
    Sánchez-Diz P; Estany-Gestal A; Aguirre C; Blanco A; Carracedo A; Ibáñez L; Passiu M; Provezza L; Ramos-Ruiz R; Ruiz B; Salado-Valdivieso I; Velasco EA; Figueiras A
    Pharmacogenomics J; 2009 Oct; 9(5):306-10. PubMed ID: 19381164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Association of polymorphisms of cytochrome P450 2C9 exon 4 and -65G>C with warfarin sensitivity].
    Wang ZX; Huang L; Cai H; Men JL; Wei MX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Aug; 27(4):428-32. PubMed ID: 20677151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.
    Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H
    Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
    Sanderson S; Emery J; Higgins J
    Genet Med; 2005 Feb; 7(2):97-104. PubMed ID: 15714076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
    Tai G; Farin F; Rieder MJ; Dreisbach AW; Veenstra DL; Verlinde CL; Rettie AE
    Pharmacogenet Genomics; 2005 Jul; 15(7):475-81. PubMed ID: 15970795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.
    Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E
    Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Warfarin dose related to apolipoprotein E (APOE) genotype.
    Kohnke H; Sörlin K; Granath G; Wadelius M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):381-8. PubMed ID: 15952022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.